DOCSLIB.ORG

New Frontiers

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
New Frontiers PROGRAM & BOOK OF ABSTRACTS JUNE 13-16, 2009 • PORTLAND, OREGON New Frontiers Children’s Tumor FoundaTION 95 PINE STREET, 16TH FLOOR, NEW YORK, NY 10005 | WWW.CTF.ORG | 212.344.6633 Dear NF Conference Attendees: On behalf of the Children’s Tumor Foundation, welcome to the 2009 NF Conference: New Frontiers. The theme references the meeting content and also Portland itself, historically a gateway port of the Pacific North West. The urban setting offers a ‘new frontier’ in comparison to the mountain and beach locales of past NF Conferences, but one which we feel you will enjoy. Portland is an easy-going city offering history, beauty and relaxation – features encapsulated in our host hotel The Nines, itself a part of the tapestry of Portland history, renovated from the former landmark Meier & Frank department store. The last year has seen major NF research advances. The dovetailing of discovery, translation and the clinic can be seen throughout the meeting. We are firmly in the age of NF clinical trials and proud that the Children’s Tumor Foundation is part of this advance: in 2009 we funded our first two pilot Clinical Trial Awards. We continue to build a pipeline of candidate NF drug therapies through the Foundation’s multi-center NF Preclinical Consortium and the seed grant Drug Discovery Initiative (DDI) program. Through these translational initiatives we are cultivating NF collaborations with the biotechnology and pharmaceutical sector, a critical factor in moving NF research forward to the clinic. At the same time, basic research advances continue, such as in the unraveling of schwannomatosis. Through our Schwannomatosis Awards program, the Foundation has committed around $500,000 to schwannomatosis since INI-1 was identified as a candidate gene in 2007. This includes discovery research, genesis of schwannomatosis mouse models and now, establishing a Schwannomatosis Natural History Database. Underpinning the bench-to-bedside pathway is the Foundation’s NF Clinic Network, now 38 Affiliate Clinics in the United States and growing. NFCN strives to improve NF clinical care and to build bridges with the NF patient community. In planning is the addition of an NF BioBank and Patient Registry, to facilitate researcher access to NF tissue and clinical data, and empower NF patients to participate in accelerating NF research to the clinic. We still face many frontiers on the road to ending neurofibromatosis, but let’s celebrate the path we have carved so far. Enjoy the meeting! Sincerely, Kim Hunter-Schaedle, Ph.D. John W. Risner Chief Scientific Officer President CONTENTS Table of Contents INTRODUCTION Research Programs of the Children’s Tumor Foundation .....................................5 Foundation Staff at the 2009 NF Conference .......................................................6 Children’s Tumor Foundation National Programs .................................................7 CME Credits - NYU Welcome Letter and Course Description ................................10 INFORMATION Schedule At-A-Glance ........................................................................................16 Important Notes To Chairs, Speakers & Poster Presenters ...................................17 Vote For Your Favorite Posters ............................................................................18 Schedule ...........................................................................................................19 ABSTRACTS Keynote Presentations .......................................................................................27 Session 1: NF Clinical Trials Updates ..................................................................29 Session 2: Correlating NF Phenotype and Genotype ............................................33 Session 3A: Clinical Features of NF ....................................................................35 Session 3B: Molecular Basis of Tumors in NF .....................................................37 Session 4A: NF1 in Context: A View of Related Ras-MAPK Disorders ...................40 Session 4B: Basic - Unraveling the Signaling Pathways of NF ..............................43 Session 5B: Basic - Unraveling the Signaling Pathways of NF (cont.) ...................46 Session 6: Recent Advances in Understanding NF1 Cognitive Deficits ..................48 Session 7: NF2 and Schwannomatosis: What’s New? .........................................50 Session 8A: Novel Cellular and Animal Models of NF ...........................................53 Session 8B: Progress in Management of NF1 Bone Abnormalities .......................56 Session 9: NF Therapeutic Targets and Preclinical Drug Screening .......................60 POSTERS Poster Presentation: Session 1 (odd numbers) ...................................................63 Poster Presentation: Session 2 (even numbers) ..................................................83 APPENDIX Attendees List - 2009 NF Conference .................................................................103 Maps ................................................................................................................106 4 | Children’s Tumor Foundation • Ending Neurofibromatosis Through Research RESEARCH PROGRAMS Research Programs of the Children’s Tumor Foundation The Children’s Tumor Foundation is dedicated to ending neurofibromatosis (NF) through research. For over 25 years, Research Programs of the Children’s Tumor Foundation .....................................5 the Foundation has funded NF research with the goal of identifying NF drug therapies and improving the lives of those Foundation Staff at the 2009 NF Conference .......................................................6 living with the disorder. To date, the Foundation has committed over $30M to NF research initiatives. The Foundation also provides resources for NF patients and their families, and endeavors to increase public awareness of NF. Children’s Tumor Foundation National Programs .................................................7 CME Credits - NYU Welcome Letter and Course Description................................10 The Foundation has been a long-time key advocate for federal support of NF research. The Foundation works closely with the National Institutes of Health and has been instrumental in the inception and continuation of the United States Schedule At-A-Glance........................................................................................ 16 Army’s Congressionally Directed Medical Research Program. Important Notes To Chairs, Speakers & Poster Presenters................................... 17 Vote For Your Favorite Posters............................................................................ 18 The research programs of the Children’s Tumor Foundation support discovery and translational research, clinical trials and clinical care. Schedule........................................................................................................... 19 Keynote Presentations .......................................................................................27 Open Programs: Call for Applications Session 1: NF Clinical Trials Updates.................................................................. 29 • Young Investigator Awards: Our longest running research program provides two year grants for pre- and post­ Session 2: Correlating NF Phenotype and Genotype ............................................33 doctoral researchers in NF research. YIA continues as a cornerstone program of the Foundation. Many of today’s Session 3A: Clinical Features of NF ....................................................................35 NF community leaders are former YIA recipients. Next deadline: early 2010. Session 3B: Molecular Basis of Tumors in NF..................................................... 37 • Drug Discovery Initiative Awards: Grants of up to $50,000 for pilot preclinical drug screening. To date, this Session 4A: NF1 in Context: A View of Related Ras-MAPK Disorders...................40 program has funded 25 drug screens. Multiple deadlines: see www.ctf.org. Session 4B: Basic - Unraveling the Signaling Pathways of NF.............................. 43 • Clinical Trial Awards: Offer $125,000 to conduct small-scale pilot clinical trials of candidate NF therapeutics. Session 5B: Basic - Unraveling the Signaling Pathways of NF (cont.)................... 46 Deadline: Letter of Intent required. Contact the Foundation first. Session 6: Recent Advances in Understanding NF1 Cognitive Deficits.................. 48 • NF Clinic Network (CTF-NFCN): Recognizes those clinics offering comprehensive NF clinical care. Session 7: NF2 and Schwannomatosis: What’s New?.........................................50 Now 38 Affiliate Clinics. Any clinic may apply for participation. U.S. Clinics eligible to receive seed funding to Session 8A: Novel Cellular and Animal Models of NF........................................... 53 expand clinic activities. Deadlines: February 28th and August 31st. Session 8B: Progress in Management of NF1 Bone Abnormalities .......................56 Session 9: NF Therapeutic Targets and Preclinical Drug Screening.......................60 Ongoing Programs (no current call for applications) • The NF Preclinical Consortium: part of a $5M effort to advance NF research in the clinics. Research teams at six Poster Presentation: Session 1 (odd numbers) ...................................................63 centers collaborating in screening the most promising candidate NF therapeutics in multiple
Load more

Recommended publications
  • Revision of Diagnostic Criteria for Neurofibromatosis
    Revision of Diagnostic Criteria for Neurofibromatosis Gareth Evans, MD, St. Mary’s Hospital/University of Manchester, UK Susan Huson, MD, Consultant Geneticist, UK Eric Legius, MD, PhD, University of Leuven, Belgium Ludwine Messiaen, PhD, University of AlaBama, Birmingham, USA Scott Plotkin, MD, PhD, Massachusetts General Hospital, USA Pierre Wolkenstein, MD, PhD, Hôpital Henri-Mondor, France 2019 NF Conference San Francisco, CA September 21, 2019 Revision of the Diagnostic Criteria of the Neurofibromatoses 92 medical specialists 20 countries 5 continents We want your feedback! Send email to: [email protected] Participants in revision process: Leadership team Clinical Epidemiology Health Services Research: Ophthalmology: • Gareth Evans • Nilton Rezende • Vanessa Merker • Robert Avery • Sue Huson • Catherine Cassiman • Eric Legius Clinical Genetics: Internal Medicine: Pathology: • Ludwine Messiaen • Dorothy Halliday • Luiz Oswaldo Carneiro • Karin Cunha • Scott Plotkin • Maurizio Clementi Rodrigues • Anat Stemmer-Rachamimov • Pierre Wolkenstein • Arvid Heiberg • Patrice Pancza • Joanne Ngeow Scientists: Pediatrics: • Shay Ben-Schachar • Miriam Smith • Outside Experts: • Bruce Korf • Marco Giovannini Rianne Oostenbrink • • Monique Anten • Mimi Berman • Eduard Serra Robert Listernick • Jaan Toelen • Betty Schorry • Juha Peltonen Pediatric Hematology and • Arthur Aylsworth • Gareth Evans Oncology: • Meredith Wilson • Ignacio Blanco Molecular Genetics: • Michael Fisher • Helen Hanson • Dusica Babovic-Vuksanovic •Laura Papi • Christopher
    [Show full text]
  • 2018 Abstract Book
    CONTENTS Table of Contents INFORMATION Continuing Medical Education .................................................................................................5 Guidelines for Speakers ..........................................................................................................6 Guidelines for Poster Presentations .........................................................................................8 SPEAKER ABSTRACTS Abstracts ...............................................................................................................................9 POSTER ABSTRACTS Basic Research (Location – Room 101) ...............................................................................63 Clinical (Location – Room 8) ..............................................................................................141 2018 Joint Global Neurofibromatosis Conference · Paris, France · November 2-6, 2018 | 3 4 | 2018 Joint Global Neurofibromatosis Conference · Paris, France · November 2-6, 2018 EACCME European Accreditation Council for Continuing Medical Education 2018 Joint Global Neurofibromatosis Conference Paris, France, 02/11/2018–06/11/2018 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) for a maximum of 27 European CME credits (ECMEC®s). Each medical specialist should claim only those credits that he/she actually spent in the educational activity. The EACCME® is an institution of the European Union of Medical Specialists (UEMS), www.uems.net. Through an agreement between
    [Show full text]
  • Schwannomatosis: Tumors That Affect the Nervous System
    In partnership with Primary Children’s Hospital Schwannomatosis: Tumors that affect the nervous system Schwannomatosis (sh-WAHN-no-muh-TOH-siss) is a genetic What are the signs disorder that causes noncancerous (benign) tumors, of schwannomatosis? called schwannomas, to grow on the peripheral and Signs of schwannomatosis include: spinal nerves. These tumors can cause pain that are • Chronic pain anywhere in the body hard to control. (caused by schwannomas pushing on the nerves) One in 40,000 people worldwide develop • Numbness or tingling schwannomatosis, a rare form of neurofibromatosis (new-roh-FIBE-row-muh-TOH-siss) each year. • Headaches Neurofibromatosis is a group of genetic disorders • Vision changes that affect the nervous system. • Weakness (including facial weakness) What causes schwannomatosis? • Problems with bowel movements Because schwannomatosis is a genetic disorder, your child either: • Trouble urinating • Inherited an abnormal gene from a parent, or Your child may have mild or severe pain, and they • Inherited a gene mutation may not have other symptoms of schwannomatosis until later. This makes it hard to diagnose Many children who have schwannomatosis are the the disorder. first in their family to have symptoms of the disorder. However, these children can then pass How is schwannomatosis diagnosed? schwannomatosis to their own children. Your child’s healthcare provider will look at your child and ask questions about their pain and symptoms. Sometimes the provider may be able to feel a tumor during a physical exam,
    [Show full text]
  • DGCR8 Microprocessor Defect Characterizes Familial Multinodular Goiter with Schwannomatosis
    The Journal of Clinical Investigation CLINICAL MEDICINE DGCR8 microprocessor defect characterizes familial multinodular goiter with schwannomatosis Barbara Rivera,1,2,3 Javad Nadaf,2,3 Somayyeh Fahiminiya,4 Maria Apellaniz-Ruiz,2,3,4,5 Avi Saskin,5,6 Anne-Sophie Chong,2,3 Sahil Sharma,7 Rabea Wagener,8 Timothée Revil,5,9 Vincenzo Condello,10 Zineb Harra,2,3 Nancy Hamel,4 Nelly Sabbaghian,2,3 Karl Muchantef,11,12 Christian Thomas,13 Leanne de Kock,2,3,5 Marie-Noëlle Hébert-Blouin,14 Angelia V. Bassenden,15 Hannah Rabenstein,8 Ozgur Mete,16,17 Ralf Paschke,18,19,20,21,22 Marc P. Pusztaszeri,23 Werner Paulus,13 Albert Berghuis,15 Jiannis Ragoussis,4,9 Yuri E. Nikiforov,10 Reiner Siebert,8 Steffen Albrecht,24 Robert Turcotte,25,26 Martin Hasselblatt,13 Marc R. Fabian,1,2,3,7,15 and William D. Foulkes1,2,3,4,5,6 1Gerald Bronfman Department of Oncology, McGill University, Montreal, Quebec, Canada. 2Lady Davis Institute for Medical Research and 3Segal Cancer Centre, Jewish General Hospital, Montreal, Quebec, Canada. 4Cancer Research Program, McGill University Health Centre, Montreal, Quebec, Canada. 5Department of Human Genetics, McGill University, Montreal, Quebec, Canada. 6Division of Medical Genetics, Department of Medicine, McGill University Health Centre and Jewish General Hospital, Montreal, Quebec, Canada. 7Department of Experimental Medicine, McGill University, Montreal, Quebec, Canada. 8Institute of Human Genetics, University of Ulm and University of Ulm Medical Center, Ulm, Germany. 9Génome Québec Innovation Centre, McGill University, Montreal, Quebec, Canada. 10Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA. 11Department of Diagnostic Radiology, McGill University, Montreal, Quebec, Canada.
    [Show full text]
  • Teri Melese, Ph.D
    Prepared: 02/015 University of California, San Diego Curriculum Vitae Name: Teri Melese, Ph.D Current Position: UCSD Assistant Vice Chancellor, Industry Research Alliances Adjunct Associate Professor, Department of Medicine and Rady School of Management Last Position Held: Adjunct Associate Professor UCSF Department of Medicine, School of Medicine, 2005-2012 UCSF Dean’s Office: Director of Business Strategy and Development, School of Medicine UCSF Helen Diller Comprehensive Cancer Center Executive Committee: Associate Director for Strategic Alliances Address: University of California, San Diego Office of Research Affairs 9500 Gilman Drive #0910 La Jolla, CA 92093-0043 Tel: (858) 822-5247 mobile: (408) 373-3651 [email protected] Education: 1975-77 University of California, Berkeley A.B. Neurobiology/ Literature 1977-82 University of California, San Francisco Ph.D. Regents Fellow 1982-86 University of California, Los Angeles Postdoctoral Fellow Biochemistry 1986-87 University of California, Los Angeles American Cancer Sr. Research Fellow Molecular Biology Principal Positions Held: 1988-92 Columbia University, New York Assistant Professor Biological Sciences 1993-97 Columbia University, New York Associate Professor Biological Sciences 1997-99 Columbia University, New York Adjunct Associate Professor Biological Sciences 1997-01 Iconix Pharmaceuticals Mountain View Founding Member & Director Chemical Genomics 2001-2012 University of California, San Francisco Adjunct Full Professor Step II Medicine Present University of California, San Diego
    [Show full text]
  • Molecular Chaperones in Cancer
    CNIO - SPANISH”LA CAIXA”NATIONAL CANCER FOUNDATION RESEARCH CENTRE FRONTIERS MEETINGS 2017 Madrid 2nd- 4th May 2017 MOLECULAR CHAPERONES IN CANCER IN MEMORY OF SUSAN LINDQUIST Organisers Nabil Djouder Spanish National Cancer Research Centre (CNIO), Madrid, Spain Wilhelm Krek Institute for Molecular Health Sciences Zurich, Switzerland Paul Workman The Institute of Cancer Research London, UK Xiaohong Helena Yang Cancer Cell Cambridge, US EXCELENCIA MINISTERIO DE ECONOMÍA, INDUSTRIA SEVERO Y COMPETITIVIDAD OCHOA CNIO - SPANISH”LA CAIXA”NATIONAL CANCER FOUNDATION RESEARCH CENTRE FRONTIERS MEETINGS 2017 Madrid 2nd- 4th May 2017 MOLECULAR CHAPERONES IN CANCER CNIO - SPANISH”LA CAIXA”NATIONAL CANCER FOUNDATION RESEARCH CENTRE FRONTIERS MEETINGS 2017 Madrid 2nd- 4th May 2017 MOLECULAR CHAPERONES IN CANCER Summary 07 PROGRAMME 19 KEYNOTE LECTURE 23 SESSIONS 23 S #1 PROTEIN QUALITY CONTROL 31 S #2 FOLDING, MISFOLDING AND AGGREGATION 41 S #3 STRESS MECHANISMS IN CANCER 49 S #4 CHAPERONES IN CANCER 59 S #5 TARGETING CHAPERONES: CHAPERONOTHERAPY 67 CLOSING LECTURE 69 ORGANISERS AND SPEAKERS’ BIOGRAPHIES 99 POSTER SESSIONS 119 Previous CNIO Frontiers Meetings and CNIO Cancer Conferences 05 CNIO - SPANISH”LA CAIXA”NATIONAL CANCER FOUNDATION RESEARCH CENTRE FRONTIERS MEETINGS 2017 Madrid 2nd- 4th May 2017 MOLECULAR CHAPERONES IN CANCER PROGRAMME 07 PROGRAMME Madrid 2nd- 4th May 2017 MOLECULAR CHAPERONES IN CANCER Venue: Spanish National Cancer Research Centre – CNIO Auditorium, Madrid, Spain Chairpersons and organizing committee: Nabil Djouder, Spanish National Cancer Research Centre, Madrid, Spain Wilhelm Krek, Institute for Molecular Health Sciences, ETH, Zurich, Switzerland Paul Workman, The Institute of Cancer Research, London, UK Xiaohong Helena Yang, Cancer Cell, Cambridge, USA Rationale: Molecular chaperones play key roles in the folding, stability and activity of proteins in normal cell homeostasis and disease pa- thology, including cancer.
    [Show full text]
  • Newly Diagnosed with Schwannomatosis: a Guide to the Basics
    NEWLY DIAGNOSED WITH SCHWANNOMATOSIS: A GUIDE TO THE BASICS ctf.org 1-800-323-7938 CONTENTS Newly Diagnosed? You Are Not Alone 2 The Children’s Tumor Foundation 4 NF Basics 5 Understanding Schwannomatosis Symptoms 6 Inheritance and Genetics of Schwannomatosis 7 How Is the Diagnosis Made? 10 Medical Management of Schwannomatosis 11 Sharing the News 13 Connecting with Other Patients and Families 15 Schwannomatosis Research 16 Insurance Coverage for Schwannomatosis 17 Resources 18 NEWLY DIAGNOSED? You Are Not Alone We at the Children’s Tumor Foundation (CTF) understand that many questions and concerns arise after receiving a diagnosis of schwannomatosis, a form of neurofibromatosis, or NF. There’s a lot of information to absorb at one time, and you probably want to know how your diagnosis will impact your life. It can be helpful to remember that different people may deal with health-related news in different ways. While some prefer to digest small bits of information at a time, others like to get as much information as possible right away. Both of these approaches are perfectly normal. It’s important to know that the symptoms of schwannomatosis vary widely, and most people with the condition continue to lead full and active lives under the care of an experienced specialist who can manage their symptoms and watch for potential complications. This brochure is designed to give you essential information about schwannomatosis as well as provide key advice and resources so that you can take care of your health and continue to get the most out of life. 2 As you begin your journey of learning more about schwannomatosis, we also want you to know that you are not alone.
    [Show full text]
  • C-Fiber Loss As a Possible Cause of Neuropathic Pain in Schwannomatosis
    International Journal of Molecular Sciences Article C-Fiber Loss as a Possible Cause of Neuropathic Pain in Schwannomatosis 1, , 2,3 4 1 Said C. Farschtschi * y , Tina Mainka , Markus Glatzel , Anna-Lena Hannekum , Michael Hauck 1,5, Mathias Gelderblom 1, Christian Hagel 4 , Reinhard E. Friedrich 6, Martin U. Schuhmann 7, Alexander Schulz 8,9, Helen Morrison 8, Hildegard Kehrer-Sawatzki 10, 1 1 11 11,12, Jan Luhmann , Christian Gerloff , Martin Bendszus , Philipp Bäumer z and 1, Victor-Felix Mautner z 1 Department of Neurology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany; [email protected] (A.-L.H.); [email protected] (M.H.); [email protected] (M.G.); [email protected] (J.L.); gerloff@uke.de (C.G.); [email protected] (V.-F.M.) 2 Department of Neurology, Charité University Medicine, 10117 Berlin, Germany; [email protected] 3 Berlin Institute of Health, 10178 Berlin, Germany 4 Department of Neuropathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany; [email protected] (M.G.); [email protected] (C.H.) 5 Department of Neurophysiology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany 6 Department of Maxillofacial Surgery, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany; [email protected] 7 Department of Neurosurgery, University Medical Center Tübingen, 72076 Tübingen, Germany; [email protected] 8 Leibniz Institute on Aging, Fritz Lipmann Institute, 07745 Jena, Germany; [email protected] (A.S.); helen.morrison@leibniz-fli.de (H.M.) 9 MVZ Human Genetics, 99084 Erfurt, Germany 10 Institute of Human Genetics, University of Ulm, 89081 Ulm, Germany; [email protected] 11 Department of Neuroradiology, University Medical Center Heidelberg, 69120 Heidelberg, Germany; [email protected] (M.B.); [email protected] (P.B.) 12 Department of Radiology, German Cancer Research Center, 69120 Heidelberg, Germany * Correspondence: [email protected]; Tel.: +49(0)407410-53869 Martinistr.
    [Show full text]
  • Current Understanding of Neurofibromatosis Type 1, 2, And
    International Journal of Molecular Sciences Review Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis Ryota Tamura Department of Neurosurgery, Kawasaki Municipal Hospital, Shinkawadori, Kanagawa, Kawasaki-ku 210-0013, Japan; [email protected] Abstract: Neurofibromatosis (NF) is a neurocutaneous syndrome characterized by the development of tumors of the central or peripheral nervous system including the brain, spinal cord, organs, skin, and bones. There are three types of NF: NF1 accounting for 96% of all cases, NF2 in 3%, and schwannomatosis (SWN) in <1%. The NF1 gene is located on chromosome 17q11.2, which encodes for a tumor suppressor protein, neurofibromin, that functions as a negative regulator of Ras/MAPK and PI3K/mTOR signaling pathways. The NF2 gene is identified on chromosome 22q12, which encodes for merlin, a tumor suppressor protein related to ezrin-radixin-moesin that modulates the activity of PI3K/AKT, Raf/MEK/ERK, and mTOR signaling pathways. In contrast, molecular insights on the different forms of SWN remain unclear. Inactivating mutations in the tumor suppressor genes SMARCB1 and LZTR1 are considered responsible for a majority of cases. Recently, treatment strategies to target specific genetic or molecular events involved in their tumorigenesis are developed. This study discusses molecular pathways and related targeted therapies for NF1, NF2, and SWN and reviews recent clinical trials which involve NF patients. Keywords: neurofibromatosis type 1; neurofibromatosis type 2; schwannomatosis; molecular tar- geted therapy; clinical trial Citation: Tamura, R. Current Understanding of Neurofibromatosis Int. Type 1, 2, and Schwannomatosis. 1. Introduction J. Mol. Sci. 2021, 22, 5850. https:// doi.org/10.3390/ijms22115850 Neurofibromatosis (NF) is a genetic disorder that causes multiple tumors on nerve tissues, including brain, spinal cord, and peripheral nerves [1–3].
    [Show full text]
  • Pregnancy with Neurofibromatosis Type II: the Enigma Continues
    International Journal of Reproduction, Contraception, Obstetrics and Gynecology Pandey A et al. Int J Reprod Contracept Obstet Gynecol. 2015 Jun;4(3):869-870 www.ijrcog.org pISSN 2320-1770 | eISSN 2320-1789 DOI: 10.18203/2320-1770.ijrcog20150113 Case Report Pregnancy with neurofibromatosis type II: the enigma continues Ankita Pandey*, Minakshi Tripathi, Simantini Bose, Balaji Jadhav, Y. S. Nandanwar Department of Obstetrics & Gynaecology, LTMMC&GH, Sion, Mumbai, Maharashtra, India Received: 11 March 2015 Revised: 18 March 2015 Accepted: 18 April 2015 *Correspondence: Dr. Ankita Pandey, E-mail: [email protected] Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT Neurofibromatosis type II in pregnancy has variable presentations. The recurrence rate and bilaterality of CP angle tumour is very high. We present a case of bilateral schwanomma diagnosed in midpregnancy, for which patient was operated in second trimester and postpartum radiotherapy will now be given. Keywords: Neurofibromatosis, Schwanomma, Autosomal dominant trait, Spinal anaesthesia INTRODUCTION Patient is a known case of neurofibromatosis type II and was diagnosed to have bilateral cerebellopontine angle Neurofibromatosis type II affects about 1 in every 40000 schwanomma in April 2014. She underwent right people without regard to sex or race. They are at high risk retrosigmoid craniotomy with excision of right CP angle of developing tumours (Schwanomma) on both nerves to in 9th October 2014. She then complained of swelling and the ears.
    [Show full text]
  • LONG-TERM MEMBERS 25+ Years of Membership
    LONG-TERM MEMBERS 25+ Years of Membership Stuart A. Aaronson, MD Stephen P. Ackland, MBBS Carol Aghajanian, MD Steven A. Akman, MD Icahn School of Medicine at Mount Sinai University of Newcastle Memorial Sloan Kettering Cancer Center Roper St. Francis Healthcare United States Australia United States United States Active Member Active Member Active Member Active Member 38 Years of Membership 33 Years of Membership 27 Years of Membership 35 Years of Membership Cory Abate-Shen, PhD Edward M. Acton, PhD Irina U. Agoulnik, PhD Emmanuel T. Akporiaye, PhD Columbia University Irving Medical United States Florida International University Verana Therapeutics Center Emeritus Member United States United States United States 42 Years of Membership Active Member Emeritus Member Active Member 25 Years of Membership 31 Years of Membership 26 Years of Membership David J. Adams, PhD Duke University Medical Center Imran Ahmad, PhD Ala-Eddin Al Moustafa, PhD James L. Abbruzzese, MD United States Northwestern Medicine McGill University Duke University Emeritus Member United States Canada United States 32 Years of Membership Active Member Active Member Active Member 25 Years of Membership 26 Years of Membership 32 Years of Membership Gregory P. Adams, PhD Elucida Oncology Nihal Ahmad, PhD Abdul Al Saadi, PhD Ehtesham A. Abdi, MBBS United States Univ. of Wisconsin Madison Sch. of Med. William Beaumont Hospital The Tweed Hospital Active Member & Public Health United States Australia 29 Years of Membership United States Emeritus Member Emeritus Member Active Member 52 Years of Membership 33 Years of Membership Lucile L. Adams-Campbell, PhD 25 Years of Membership Georgetown Lombardi Comprehensive Suresh K.
    [Show full text]
  • LZTR1: a Promising Adaptor of the CUL3 Family (Review)
    ONCOLOGY LETTERS 22: 564, 2021 LZTR1: A promising adaptor of the CUL3 family (Review) HUI ZHANG*, XINYI CAO*, JIAN WANG, QIAN LI, YITING ZHAO and XIAOFENG JIN Department of Biochemistry and Molecular Biology; Zhejiang Key Laboratory of Pathophysiology, Medical School of Ningbo University, Ningbo, Zhejiang 315211, P.R. China Received October 22, 2020; Accepted May 7, 2021 DOI: 10.3892/ol.2021.12825 Abstract. The study of the disorders of ubiquitin‑mediated 1. Introduction proteasomal degradation may unravel the molecular basis of human diseases, such as cancer (prostate cancer, lung cancer Ubiquitylation is a key post‑translational modification that and liver cancer, etc.) and nervous system disease (Parkinson's plays a significant role in the stability of the intracellular disease, Alzheimer's disease and Huntington's disease, etc.) environment, cell proliferation and differentiation, as well and help in the design of new therapeutic methods. Leucine as various other cellular functions (1). An imbalance in zipper‑like transcription regulator 1 (LZTR1) is an important ubiquitination‑mediated protein degradation can represent the substrate recognition subunit of cullin‑RING E3 ligase that molecular basis of certain human diseases, such as cancers plays an important role in the regulation of cellular functions. (prostate cancer, lung cancer and liver cancer) and nervous Mutations in LZTR1 and dysregulation of associated down‑ system diseases (Parkinson's disease, Alzheimer's disease stream signaling pathways contribute to the pathogenesis of and Huntington's disease) (1). Ubiquitin is activated in an Noonan syndrome (NS), glioblastoma and chronic myeloid ATP‑dependent reaction catalyzed by the ubiquitin‑activating leukemia. Understanding the molecular mechanism of the enzyme E1 (2,3).
    [Show full text]